Abstract
Various derivatives of a modified estradiol core bearing a fused γ-lactone were designed as non-estrogenic inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1). The compounds were synthesized, characterized and tested for their ability to inhibit enzyme activity (transformation of estrone into estradiol). The proliferative (estrogenic) activity of the compounds was also investigated on estrogen-sensitive breast cancer T-47D cells. Interestingly, one of the estradiol derivatives (compound 24) showed a dual action by inhibiting 17β-HSD1 (IC50 = 1.0 µM) and by producing an antiestrogenic effect on T-47D cells.
Keywords: Chemical synthesis, enzyme inhibitor, estrogen, lactone, steroid, 17β-hydroxysteroid dehydrogenase.
Current Enzyme Inhibition
Title:Synthesis and Biological Evaluation of Estradiol-Core Derivatives Bearing a Fused γ-Lactone as Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1
Volume: 10 Issue: 1
Author(s): Etienne Ouellet, Diana Ayan and Donald Poirier
Affiliation:
Keywords: Chemical synthesis, enzyme inhibitor, estrogen, lactone, steroid, 17β-hydroxysteroid dehydrogenase.
Abstract: Various derivatives of a modified estradiol core bearing a fused γ-lactone were designed as non-estrogenic inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1). The compounds were synthesized, characterized and tested for their ability to inhibit enzyme activity (transformation of estrone into estradiol). The proliferative (estrogenic) activity of the compounds was also investigated on estrogen-sensitive breast cancer T-47D cells. Interestingly, one of the estradiol derivatives (compound 24) showed a dual action by inhibiting 17β-HSD1 (IC50 = 1.0 µM) and by producing an antiestrogenic effect on T-47D cells.
Export Options
About this article
Cite this article as:
Ouellet Etienne, Ayan Diana and Poirier Donald, Synthesis and Biological Evaluation of Estradiol-Core Derivatives Bearing a Fused γ-Lactone as Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1, Current Enzyme Inhibition 2014; 10 (1) . https://dx.doi.org/10.2174/1573408010666140118002739
DOI https://dx.doi.org/10.2174/1573408010666140118002739 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Proteinase-Activated Receptor 2 (PAR2): A Challenging New Target for Treatment of Vascular Diseases
Current Pharmaceutical Design A 1536-Well Fluorescence Polarization Assay to Screen for Modulators of the MUSASHI Family of RNA-Binding Proteins
Combinatorial Chemistry & High Throughput Screening Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Acridone-based Antitumor Agents: A Mini-review
Anti-Cancer Agents in Medicinal Chemistry Natural Polymeric Nanoparticles for Brain-Targeting: Implications on Drug and Gene Delivery
Current Pharmaceutical Design The Involvement of TNF-α in Cognitive Dysfunction Associated with Major Depressive Disorder: An Opportunity for Domain Specific Treatments
Current Neuropharmacology Local Gene Delivery for Cancer Therapy
Current Gene Therapy Role of Regulatory T Cells in Allergy: Implications for Therapeutic Strategy
Inflammation & Allergy - Drug Targets (Discontinued) Regulation of Angiogenesis by the Small Heat Shock Protein αB-Crystallin
Current Angiogenesis (Discontinued) COX-2 and Colorectal Cancer
Current Pharmaceutical Design Evaluation of Effect of Ligand on Cellular Internalization: A Comparative Study of Nanoparticles and Multifunctional Nanoparticles on MDA-MB-231 Cells
Current Nanoscience Anti-Angiogenic and Anti-Inflammatory Effects of Statins: Relevance to Anti-Cancer Therapy
Current Cancer Drug Targets Cancer-Related Fatigue: Still an Enigma to be Solved Quickly
Reviews on Recent Clinical Trials Decoding Novel Mechanisms and Emerging Therapeutic Strategies in Breast Cancer Resistance
Current Drug Metabolism Prodrugs and Endogenous Transporters: Are They Suitable Tools for Drug Targeting into the Central Nervous System?
Current Pharmaceutical Design Generation of Redox Imbalance Mediates the Cytotoxic Effect of Malabaricone-A in a Multidrug Resistant Cell Line
Anti-Cancer Agents in Medicinal Chemistry Overview of Base Excision Repair Biochemistry
Current Molecular Pharmacology Concepts for Nano-delivery of Therapeutic Immunomodulatory Agents
Current Bionanotechnology (Discontinued) In Vitro - In Vivo Correlation of Gene Expression Alterations Induced by Liver Carcinogens
Current Medicinal Chemistry Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective
Current Pharmaceutical Design